Amalgamated Financial’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Amalgamated Financial’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$23K	Buy	+4,729	New	+$14.2K	﹤0.01%	2706

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amalgamated Financial's VIRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2022: 4,729 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #2706 among its holdings.

69 funds tracked by Wall St. Rank hold VIRX as of Q1 2022.

Amalgamated Financial held 4,729 shares of Viracta Therapeutics, Inc. Common Stock worth $23K as of Q1 2022.
Viracta Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2706 holding.
69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.